SLV313 (1-(2,3-Dihydro-Benzo[1,4]Dioxin-5-yl)-4- [5-(4-Fluoro-Phenyl)-Pyridin-3-ylmethyl]-Piperazine Monohydrochloride): A Novel Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist Potential Antipsychotic Drug

Abstract

Combined dopamine D2 receptor antagonism and serotonin (5-HT)1A receptor agonism may improve efficacy and alleviate some side effects associated with classical antipsychotics. The present study describes the in vitro and in vivo characterization of 1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4-[5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride… (More)
DOI: 10.1038/sj.npp.1301098

Topics

15 Figures and Tables

Cite this paper

@article{McCreary2007SLV313, title={SLV313 (1-(2,3-Dihydro-Benzo[1,4]Dioxin-5-yl)-4- [5-(4-Fluoro-Phenyl)-Pyridin-3-ylmethyl]-Piperazine Monohydrochloride): A Novel Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist Potential Antipsychotic Drug}, author={Andrew C McCreary and Jeffrey Glennon and Charles R. Ashby and Herbert Yale Meltzer and Zhu Li and J M C Reinders and Mayke B. Hesselink and Stephen Kenneth Long and Arnoud H J Herremans and Herman Heinrich van Stuivenberg and Rolf W Feenstra and Chris G. Kruse}, journal={Neuropsychopharmacology}, year={2007}, volume={32}, pages={78-94} }